Tag Archives: FDA

New Treatise! FDA Deskbook: A Compliance and Enforcement Guide

FDA DeskbookFDA Deskbook: A Compliance and Enforcement Guide provides a comprehensive description of the complexities of compliance under The Federal Food, Drug, and Cosmetic Act (FDC Act) and practical suggestions on how FDA-regulated entities can avoid being the subject of an enforcement action by the federal government.  This new title fully explains the legal framework created by the FDC Act and subsequent statutes, regulations, guidance and policies governing the food and drug industry.

Written by attorneys at Hyman, Phelps & McNamara, P.C., the largest dedicated food and drug law firm in the U.S., the FDA Deskbook incorporates more than a century of cumulative experience from positions at FDA, the U.S. Department of Justice, the Drug Enforcement Administration, U.S. Attorney’s Offices, and regulated industry.  The result is this essential guidebook, which aims to assist industry stakeholders by providing a wide-ranging review of compliance and enforcement under the FDC Act and related laws.

The FDA Deskbook first details the ins-and-outs of FDA’s administrative actions (such as warning letters, import alerts, and recalls) and civil and criminal enforcement authorities.  The FDA Deskbook then walks the reader through individual chapters highlighting specific issues affecting the cross-section of FDA regulation:

  • drugs, including OTC, prescription, and compounded drugs, and controlled substances
  • medical devices, including in vitro diagnostic devices
  • food and dietary supplements
  • tobacco
  • animal products
  • cosmetics

Importantly, the FDA Deskbook contains chapters focused on today’s hot button issues, such as advertising and promotion, fraud and abuse, and good manufacturing practices.  The FDA Deskbook proposes best practice tips, including how to deal with FDA inspections, alternatives to conducting internal investigations, and potential defense strategies for use in enforcement proceedings.

The FDA Deskbook provides a thorough discussion of the current landscape necessary for FDA-regulated entities to achieve compliance and avoid enforcement action.

This essential new title is available on PLI Discover PLUS, our online research database. If you’d like to order a print copy, please email the PLI Library Help Desk or call 877-900-5291.

New Edition of Pharmaceutical Compliance and Enforcement Answer Book Now Available

 

PLI’s Pharmaceutical Compliance and Enforcement Answer Book 2015 is now available.  This Answer Book provides a comprehensive overview of the regulatory issues faced by the different participants in the pharmaceutical industry.

In an easy Q&A format, Pharmaceutical Compliance and Enforcement Answer Book 2015 describes:

 

  • The FDA’s authority and potential actions to regulate prescription drugs and biologics both before and after approval by the agency
  • A facility’s rights and compliance obligations during an inspection by the agency
  • How to best evaluate a company’s potential of being in violation and what to do to mitigate those risks
  • What advertising and promotion of prescription drugs is permitted
  • How product liability issues overlap with FDA enforcement initiatives
  • When criminal prosecution is used as part of the regulatory enforcement effort

Filled with practical suggestions, Pharmaceutical Compliance and Enforcement Answer Book 2015 provides the attorney and his or her clients with a roadmap to effective compliance with FDA pharmaceutical regulations.

If you’d like to order Pharmaceutical Compliance and Enforcement Answer Book 2015, please email the PLI Library Help Desk or call 877-900-5291.